Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice

Neurobiology of Disease

Volumn 71, Issue , 2014, Pages 140-150

  Naydenov, Alipi V ^a   Sepers, Marja D ^b   Swinney, Katie ^c   Raymond, Lynn A ^b   Palmiter, Richard D ^c   Stella, Nephi ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CB1; Dendritic spines; Endocannabinoids; Huntington's disease; R6 2 mice; Synaptic loss

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; CP 55 940; CRE RECOMBINASE; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2; CNR1 PROTEIN, MOUSE; ENHANCED GREEN FLUORESCENT PROTEIN; G PROTEIN COUPLED RECEPTOR; GPR88 PROTEIN, MOUSE; GREEN FLUORESCENT PROTEIN; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CATALEPSY; CELL DENSITY; CELL LOSS; CELL SELECTION; CELLULAR DISTRIBUTION; CNR1 GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC SPINE; DNA FLANKING REGION; DOWN REGULATION; DRUG PROTEIN BINDING; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE LOCUS; GENE TARGETING; GENETIC PARAMETERS; GENETIC RESCUE; HISTOPATHOLOGY; HUNTINGTON CHOREA; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOUSE; MOUSE MODEL; NERVE CELL PLASTICITY; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STRIATE CORTEX; SYNAPTIC TRANSMISSION; ACTION POTENTIAL; ANIMAL; CORPUS STRIATUM; GENE EXPRESSION REGULATION; GENETICS; HUNTINGTON DISEASE; METABOLISM; MOTOR ACTIVITY; MUSCLE STRENGTH; MUTATION; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SILVER STAINING; SYNAPSE; TIME; TRANSGENIC MOUSE; ULTRASTRUCTURE;

ACTION POTENTIALS; ANIMALS; CORPUS STRIATUM; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUSCLE STRENGTH; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, G-PROTEIN-COUPLED; SILVER STAINING; SYNAPSES; TIME FACTORS;

EID: 84906672436     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.08.009     Document Type: Article

References (28)

1. Abood M.E., Sorensen R.G., Stella N. Endocannabinoids: actions at non-CB1/CB2 cannabinoid receptors 2012, Springer.
2. Blázquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., Palazuelos J., Julien B., Salazar M., Börner C., Benito C., Carrasco C., Diez-Zaera M., Paoletti P., Díaz-Hernández M., Ruiz C., Sendtner M., Lucas J.J., de Yébenes J.G., Marsicano G., Monory K., Lutz B., Romero J., Alberch J., Ginés S., Kraus J., Fernández-Ruiz J., Galve-Roperh I., Guzmán M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2010, 134:119-136. 10.1093/brain/awq278.
3. Centonze D., Rossi S., Prosperetti C., Tscherter A., Bernardi G., Maccarrone M., Calabresi P. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol. Psychiatry 2005, 57:1583-1589. 10.1016/j.biopsych.2005.03.008.
4. Cepeda C., Hurst R.S., Calvert C.R., Hernández-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 2003, 23:961-969.
5. Cepeda C., Galvan L., Holley S.M., Rao S.P., Andre V.M., Botelho E.P., Chen J.Y., Watson J.B., Deisseroth K., Levine M.S. Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models. J. Neurosci. 2013, 33:7393-7406. 10.1523/JNEUROSCI.2137-12.2013.
6. Chiarlone A., Bellocchio L., Blazquez C., Resel E., Soria-Gomez E., Cannich A., Ferrero J.J., Sagredo O., Benito C., Romero J., Sanchez-Prieto J., Lutz B., Fernández-Ruiz J., Galve-Roperh I., Guzmán M. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:8257-8262. 10.1073/pnas.1400988111.
7. Chiodi V., Uchigashima M., Beggiato S., Ferrante A., Armida M., Martire A., Potenza R.L., Ferraro L., Tanganelli S., Watanabe M., Domenici M.R., Popoli P. Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2012, 45:983-991. 10.1016/j.nbd.2011.12.017.
8. Dowie M.J., Bradshaw H.B., Howard M.L., Nicholson L.F.B., Faull R.L.M., Hannan A.J., Glass M. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 2009, 163:456-465. 10.1016/j.neuroscience.2009.06.014.
9. Dowie M.J., Howard M.L., Nicholson L.F.B., Faull R.L.M., Hannan A.J., Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience 2010, 170:324-336. 10.1016/j.neuroscience.2010.06.056.
10. Eidelberg D., Surmeier D.J. Brain networks in Huntington disease. J. Clin. Invest. 2011, 121:484-492. 10.1172/JCI45646.
11. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
12. Glass M., van Dellen A., Blakemore C., Hannan A.J., Faull R.L.M. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 2004, 123:207-212. 10.1016/S0306-4522(03)00595-5.
13. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. 1990, 87:1932-1936.
14. Horne E.A., Coy J., Swinney K., Fung S., Cherry A.E.T., Marrs W.R., Naydenov A.V., Lin Y.H., Sun X., Dirk Keene C., Grouzmann E., Muchowski P., Bates G.P., Mackie K., Stella N. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. Eur. J. Neurosci. 2012, 37. (n/a-n/a). 10.1111/ejn.12045.
15. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 2008, 14:923-930. 10.1038/nm.f.1869.
16. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.-F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 2001, 86:2667-2677.
17. Kozorovitskiy Y., Saunders A., Johnson C.A., Lowell B.B., Sabatini B.L. Recurrent network activity drives striatal synaptogenesis. Nature 2012, 1-8. 10.1038/nature11052.
18. Kreitzer A.C., Malenka R.C. Striatal plasticity and basal ganglia circuit function. Neuron 2008, 60:543-554. 10.1016/j.neuron.2008.11.005.
19. Kung V.W.S., Hassam R., Morton A.J., Jones S. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience 2007, 146:1571-1580. 10.1016/j.neuroscience.2007.03.036.
20. Luthi-Carter R., Apostol B.L., Dunah A.W., DeJohn M.M., Farrell L.A., Bates G.P., Young A.B., Standaert D.G., Thompson L.M., Cha J.-H.J. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol. Dis. 2003, 14:624-636. 10.1016/j.nbd.2003.08.024.
21. Maccarrone M., BATTISTA N., Centonze D. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog. Neurobiol. 2007, 81:349-379. 10.1016/j.pneurobio.2006.11.006.
22. Mievis S., Blum D., Ledent C. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol. Dis. 2011, 42:524-529. 10.1016/j.nbd.2011.03.006.
23. Nithianantharajah J., Barkus C., Murphy M., Hannan A.J. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol. Dis. 2008, 29:490-504. 10.1016/j.nbd.2007.11.006.
24. Pouladi M.A., Stanek L.M., Xie Y., Franciosi S., Southwell A.L., Deng Y., Butland S., Zhang W., Cheng S.H., Shihabuddin L.S., Hayden M.R. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet. 2012, 21:2219-2232. 10.1093/hmg/dds037.
25. Quintana A., Sanz E., Wang W., Storey G.P., Güler A.D., Wanat M.J., Roller B.A., La Torre A., Amieux P.S., McKnight G.S., Bamford N.S., Palmiter R.D. Lack of GPR88 enhances medium spiny neuron activity and alters motor- and cue-dependent behaviors. Nat. Publ. Group 2012, 15:1547-1555. 10.1038/nn.3239.
26. Raymond L.A., Andre V.M., Cepeda C., Gladding C.M., Milnerwood A.J., Levine M.S. Review Pathophysiology of Huntington's Disease: Time-dependent Alterations in Synaptic and Receptor Function. NSC 2011, 198:252-273. 10.1016/j.neuroscience.2011.08.052.
27. Spires T.L., Grote H.E., Garry S., Cordery P.M., Van Dellen A., Blakemore C., Hannan A.J. Dendritic spine pathology and deficits in experience dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur. J. Neurosci. 2004, 19:2799-2807. 10.1111/j.1460-9568.2004.03374.x.
28. Woodman B., Butler R., Landles C., Lupton M.K., Tse J., Hockly E., Moffitt H., Sathasivam K., Bates G.P. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 2007, 72:83-97. 10.1016/j.brainresbull.2006.11.004.